适应症-话题@MedSci

#适应症#

219篇内容 | 2995人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2206607, encodeId=3b9a220660e1e, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a> <a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=惊讶！美国FDA加速批准的223种抗癌药适应症，仅三分之一后续有统计学上的生存期改善！, objectType=article, longId=826299, objectId=da2d82629997, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240525/1716652275159_92910.jpg, objectUrl=/article/show_article.do?id=da2d82629997, replyNumber=0, likeNumber=67, createdTime=2024-05-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=da2d82629997, moduleTitle=惊讶！美国FDA加速批准的223种抗癌药适应症，仅三分之一后续有统计学上的生存期改善！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da2d82629997)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1336881, encodeId=3e9f133688182, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=君实生物阿达木单抗增加适应症补充申请获得受理, objectType=article, longId=737115, objectId=5ce7e37115c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce7e37115c5, replyNumber=0, likeNumber=114, createdTime=2022-08-28, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce7e37115c5, moduleTitle=君实生物阿达木单抗增加适应症补充申请获得受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ce7e37115c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336880, encodeId=b2f3133688013, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=从“0”到“1”全线布局，替雷利珠单抗引领肿瘤免疫治疗新浪潮，已获批9大适应症，5项已纳入医保！, objectType=article, longId=734878, objectId=0da1e3487825, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0da1e3487825, replyNumber=0, likeNumber=123, createdTime=2022-08-07, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0da1e3487825, moduleTitle=从“0”到“1”全线布局，替雷利珠单抗引领肿瘤免疫治疗新浪潮，已获批9大适应症，5项已纳入医保！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0da1e3487825)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336879, encodeId=650a13368e9d1, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=国家集采设置“隐藏关”：分适应症报量采购，政策执行精细化, objectType=article, longId=730758, objectId=66cfe307587c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cfe307587c, replyNumber=0, likeNumber=113, createdTime=2022-06-30, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cfe307587c, moduleTitle=国家集采设置“隐藏关”：分适应症报量采购，政策执行精细化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66cfe307587c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336878, encodeId=c79213368e8a0, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA委员会全票支持！辉瑞、Moderna新冠疫苗幼儿适应症即将获批, objectType=article, longId=729773, objectId=2db7e297734b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2db7e297734b, replyNumber=0, likeNumber=86, createdTime=2022-06-18, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2db7e297734b, moduleTitle=FDA委员会全票支持！辉瑞、Moderna新冠疫苗幼儿适应症即将获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2db7e297734b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336877, encodeId=d73613368e7c9, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=重磅！欧唐静®（恩格列净片）新适应症在华获批，用于治疗射血分数降低的成人心力衰竭, objectType=article, longId=729048, objectId=5b2ee29048b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b2ee29048b5, replyNumber=0, likeNumber=91, createdTime=2022-06-11, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b2ee29048b5, moduleTitle=重磅！欧唐静®（恩格列净片）新适应症在华获批，用于治疗射血分数降低的成人心力衰竭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b2ee29048b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336876, encodeId=743f13368e64a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=干货满满！11个癌种常用靶向药物适应症和用法用量大盘点, objectType=article, longId=728775, objectId=5838e287754c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5838e287754c, replyNumber=0, likeNumber=121, createdTime=2022-06-08, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5838e287754c, moduleTitle=干货满满！11个癌种常用靶向药物适应症和用法用量大盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5838e287754c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336875, encodeId=24ff13368e547, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=驯鹿生物全人源BCMA CAR-T细胞伊基仑赛注射液新增自身免疫性疾病适应症IND申请获受理, objectType=article, longId=728561, objectId=5e98e285619c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e98e285619c, replyNumber=0, likeNumber=106, createdTime=2022-06-04, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e98e285619c, moduleTitle=驯鹿生物全人源BCMA CAR-T细胞伊基仑赛注射液新增自身免疫性疾病适应症IND申请获受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e98e285619c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336874, encodeId=a08613368e400, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=重磅！单片双药HIV治疗药物多伟托®扩大适应症获批，延展至稳定转换HIV感染者, objectType=article, longId=726569, objectId=f62ae26569e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f62ae26569e6, replyNumber=0, likeNumber=132, createdTime=2022-05-12, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f62ae26569e6, moduleTitle=重磅！单片双药HIV治疗药物多伟托®扩大适应症获批，延展至稳定转换HIV感染者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f62ae26569e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336873, encodeId=a26113368e334, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=全面盘点阿达帕林的适应症、使用方法和注意事项！, objectType=article, longId=726149, objectId=3aede2614992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aede2614992, replyNumber=0, likeNumber=123, createdTime=2022-05-06, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aede2614992, moduleTitle=全面盘点阿达帕林的适应症、使用方法和注意事项！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aede2614992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336872, encodeId=0a4613368e2fd, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=国产免疫治疗药卡瑞利珠单抗适应症和不良反应大盘点！, objectType=article, longId=725912, objectId=130de259127f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=130de259127f, replyNumber=0, likeNumber=95, createdTime=2022-05-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=130de259127f, moduleTitle=国产免疫治疗药卡瑞利珠单抗适应症和不良反应大盘点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=130de259127f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336869, encodeId=285e1336869e3, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, objectType=article, longId=301601, objectId=430a301601f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430a301601f4, replyNumber=0, likeNumber=115, createdTime=2022-03-26, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430a301601f4, moduleTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=430a301601f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336868, encodeId=c6131336868c5, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知, objectType=article, longId=301548, objectId=87a330154822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87a330154822, replyNumber=0, likeNumber=98, createdTime=2022-03-25, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87a330154822, moduleTitle=关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87a330154822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336870, encodeId=e34413368e02d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代, objectType=article, longId=301171, objectId=e9013011e197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9013011e197, replyNumber=0, likeNumber=62, createdTime=2022-03-21, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9013011e197, moduleTitle=三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9013011e197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336867, encodeId=54f1133686efc, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳在欧盟递交非奈利酮用于早期慢性肾病伴2型糖尿病患者的适应症扩展申请, objectType=article, longId=300980, objectId=c76b300980ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c76b300980ba, replyNumber=0, likeNumber=138, createdTime=2022-03-18, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c76b300980ba, moduleTitle=拜耳在欧盟递交非奈利酮用于早期慢性肾病伴2型糖尿病患者的适应症扩展申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c76b300980ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336866, encodeId=fc2813368665d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA扩大了Lynparza（奥拉帕尼）的适应症范围, objectType=article, longId=300628, objectId=afbb300628bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afbb300628bb, replyNumber=0, likeNumber=97, createdTime=2022-03-14, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afbb300628bb, moduleTitle=FDA扩大了Lynparza（奥拉帕尼）的适应症范围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afbb300628bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336865, encodeId=e76a1336865be, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=赛诺菲度普利尤单抗治疗儿童湿疹适应症国内NMPA获准；全球销售达60亿美元, objectType=article, longId=300219, objectId=bbdd30021914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbdd30021914, replyNumber=0, likeNumber=91, createdTime=2022-03-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbdd30021914, moduleTitle=赛诺菲度普利尤单抗治疗儿童湿疹适应症国内NMPA获准；全球销售达60亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbdd30021914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336871, encodeId=df9d13368e19d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代！, objectType=article, longId=298947, objectId=140429894ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=140429894ed8, replyNumber=0, likeNumber=114, createdTime=2022-02-18, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=140429894ed8, moduleTitle=三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=140429894ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336863, encodeId=cf5f13368639e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折, objectType=article, longId=295103, objectId=2e0c295103eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e0c295103eb, replyNumber=0, likeNumber=96, createdTime=2022-02-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e0c295103eb, moduleTitle=礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e0c295103eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336862, encodeId=d0921336862cf, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=支原体肺炎激素适应症是什么？, objectType=article, longId=294462, objectId=66cf294462d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cf294462d9, replyNumber=0, likeNumber=82, createdTime=2022-01-23, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cf294462d9, moduleTitle=支原体肺炎激素适应症是什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66cf294462d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

适应症

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#抗癌药# #适应症#

惊讶！美国FDA加速批准的223种抗癌药适应症，仅三分之一后续有统计学上的生存期改善！

2024-05-26发表于上海

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

君实生物阿达木单抗增加适应症补充申请获得受理

2022-08-28

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

从“0”到“1”全线布局，替雷利珠单抗引领肿瘤免疫治疗新浪潮，已获批9大适应症，5项已纳入医保！

2022-08-07

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

国家集采设置“隐藏关”：分适应症报量采购，政策执行精细化

2022-06-30

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA委员会全票支持！辉瑞、Moderna新冠疫苗幼儿适应症即将获批

2022-06-18

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

重磅！欧唐静®（恩格列净片）新适应症在华获批，用于治疗射血分数降低的成人心力衰竭

2022-06-11

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

干货满满！11个癌种常用靶向药物适应症和用法用量大盘点

2022-06-08

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

驯鹿生物全人源BCMA CAR-T细胞伊基仑赛注射液新增自身免疫性疾病适应症IND申请获受理

2022-06-04

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

重磅！单片双药HIV治疗药物多伟托®扩大适应症获批，延展至稳定转换HIV感染者

2022-05-12

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

全面盘点阿达帕林的适应症、使用方法和注意事项！

2022-05-06

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

国产免疫治疗药卡瑞利珠单抗适应症和不良反应大盘点！

2022-05-02

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择

2022-03-26

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知

2022-03-25

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代

2022-03-21

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

拜耳在欧盟递交非奈利酮用于早期慢性肾病伴2型糖尿病患者的适应症扩展申请

2022-03-18

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

FDA扩大了Lynparza（奥拉帕尼）的适应症范围

2022-03-14

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

赛诺菲度普利尤单抗治疗儿童湿疹适应症国内NMPA获准；全球销售达60亿美元

2022-03-09

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

三个适应症连续获批！免疫创新药「乌帕替尼缓释片」开启银屑病关节炎靶向治疗新时代！

2022-02-18

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折

2022-02-05

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

支原体肺炎激素适应症是什么？

2022-01-23

科室
- - 订阅+
  - 更多科室
工具
服务